All In Biotech

Drug Trial Radar · NCT07929181

Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis

Multicenter Open-label Randomized Trial With an Active Control Group to Evaluate the Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Apr 10, 2024

Primary completion

Nov 28, 2024

Study completion Nov 28, 2024

Sponsor

Lead sponsor
Polisorb Joint Stock CompanyIndustry
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label, randomized Phase III clinical trial evaluated the efficacy and safety of adding Polisorb® MP, an oral colloidal silicon dioxide adsorbent, to basic therapy in adults with mild to moderate atopic dermatitis. The study included 161 patients in the efficacy analysis. Participants were randomly assigned to receive either basic therapy alone (81 patients) or basic therapy in combination with Polisorb® MP (80 patients). Basic therapy included skin care with emollients and pharmacological treatment, including cetirizine and topical pimecrolimus. The treatment period lasted 14 days, followed by an observation period. The primary endpoint was the change in the SCORAD index from baseline to Day 14. Itch intensity, dermatology-related quality of life, EASI and IGA scores were also assessed. Both groups showed improvement in disease severity during treatment. The mean SCORAD score decreased by 21.5 points in patients receiving Polisorb® MP in addition to basic therapy, compared with 17.7 points in patients receiving basic therapy alone. The difference between the groups was statistically significant (p = 0.0028), favoring the addition of Polisorb® MP. Improvements in itch intensity and IGA scores also favored combination therapy, while differences between groups in EASI changes and changes in dermatology-related quality of life were not statistically significant. A total of 34 adverse events were reported in 26 patients. No serious adverse events or deaths were reported. Gastrointestinal events, particularly constipation, were more frequent in the Polisorb® MP group. Other reported events included difficulty with defecation, abdominal discomfort, bloating, dry mouth and nausea. No new or unexpected safety concerns specific to Polisorb® MP were identified during the study. The findings indicate that adding Polisorb® MP to basic therapy was associated with a greater reduction in SCORAD scores over 14 days than basic therapy alone. The results should be interpreted in the context of the open-label design and the short treatment period.

Conditions

  • Atopic Dermatitis

Interventions

  • Colloidal Silicon DioxideDrug

    Polisorb® MP, an oral colloidal silicon dioxide adsorbent, was administered in addition to basic therapy for atopic dermatitis during the 14-day treatment period. The study evaluated the efficacy and safety of this combination compared with basic therapy alone.

  • Basic Therapy for Atopic DermatitisDrug

    Basic therapy for atopic dermatitis consisted of emollient skin care and pharmacological treatment, including cetirizine and topical pimecrolimus. It was administered for 14 days in accordance with the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Scoring Atopic Dermatitis (SCORAD) Index from Baseline to Day 14Time frame: Baseline to Day 14

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Chelyabinsk Regional Clinical Skin and Venereological Dispensary

    Chelyabinsk, Russia

  • Clinical Skin and Venereological Dispensary

    Krasnodar, Russia

  • Ryazan Regional Clinical Skin and Venereological Dispensary

    Ryazan, Russia

  • Saint Petersburg State Medical Institution 'Skin and venereological dispensary No. 10'

    Saint Petersburg, Russia

  • Reavita Med SPB LLC

    Saint Petersburg, Russia

  • Skin and venereological dispensary No. 8

    Saint Petersburg, Russia

  • City polyclinic No. 4

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.